Welcome to our dedicated page for Solana Company SEC filings (Ticker: HSDTW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to SEC filings relevant to Helius Medical Tech WT 26 (HSDTW), a warrant security associated with Helius Medical Technologies, Inc. The company files under the name Helius Medical Technologies, Inc., and its Class A common stock is listed on The Nasdaq Stock Market LLC under the symbol HSDT, as stated in multiple Form 8-K reports.
In recent Form 8-K filings, the company reports material definitive agreements involving private offerings of common stock, pre-funded warrants, stapled warrants, and warrants issued to strategic advisors. These filings describe cash and cryptocurrency-based offerings with accredited investors, where consideration may be paid in U.S. dollars, USDC, USDT, or Solana (SOL) tokens. The documents also outline lock-up provisions, stockholder approval requirements for the exercise of certain warrants, and registration rights for the resale of underlying shares.
For investors analyzing HSDTW and related securities, key filings include Form 8-K items on unregistered sales of equity securities, securities purchase or subscription agreements, strategic advisor agreements, and amendments to the company’s authorized share capital. The filings further state that net proceeds from the offerings are intended to fund the acquisition of SOL through open market purchases, support Solana treasury operations, and provide working capital and general corporate funds, subject to specified limitations.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries that explain the core terms of each document, highlight important conditions affecting warrants and common stock, and help readers understand complex capital structure changes. Real-time updates from EDGAR, along with structured access to Form 8-K items and related exhibits, allow users to review how Helius Medical Technologies, Inc. discloses its financing activities and warrant arrangements that underpin the HSDTW security.
Solana Rocket Holdings Limited and CHUNG Wai Shing have amended their ownership report for Solana Co. They jointly report beneficial ownership of 4,192,186 shares of Class A common stock, representing 9.99% of the company as of December 31, 2025.
The position is made up of 3,529,754 common shares plus pre-funded warrants for up to 10,743,213 shares and cash stapled warrants for up to 14,823,426 shares, all held by Solana Rocket. A “Beneficial Ownership Blocker” prevents them from exercising warrants if it would push their stake above 9.99%.
The 9.99% figure is calculated using 41,301,400 shares outstanding as of November 17, 2025, plus 662,432 shares issuable on partial warrant exercise. Voting and dispositive power over all 4,192,186 shares is reported as shared.
Helius Medical Technologies, Inc. filed a current report to furnish information under Regulation FD. The company stated that on September 22, 2025 it issued a press release and attached this release as Exhibit 99.1 to the report. The filing does not describe the contents of the press release, instead directing readers to the attached exhibit for details.
Helius Medical Technologies completed a $500 million PIPE on September 18, 2025 and launched a Solana-centric digital asset treasury strategy to acquire SOL via open-market purchases and build Solana treasury operations. The PIPE included cash and cryptocurrency purchasers buying combinations of common shares, pre-funded warrants and stapled warrants; exercise of the cryptocurrency-related warrants is conditioned on stockholder approval. The company’s PoNS® portable neuromodulation device is cleared in the U.S. for short-term treatment of gait deficit due to mild-to-moderate MS, authorized in Canada for three indications and is Class IIa in Australia. Common stock trades on Nasdaq under HSDT (last reported price $23.17 on September 18, 2025) and there were 39,382,328 shares outstanding as of September 18, 2025.
Helius Medical Technologies detailed large private placements of stock and warrants that raised approximately $508.7 million in gross proceeds. The company sold 37,825,277 common shares, pre-funded warrants for 36,115,912 shares, and stapled warrants for 73,941,189 shares to accredited investors in cash and cryptocurrency offerings.
Helius plans to use the net proceeds mainly to acquire SOL, the native cryptocurrency of the Solana blockchain, and to build a Solana-based treasury operation, alongside general corporate purposes. Exercise of the cryptocurrency and advisor warrants, as well as vesting of certain RSUs, depends on stockholder approvals.
The filing also describes a new Master Loan Agreement for potential short-term SOL purchases, appointment of Joseph Chee as Executive Chairman with equity-based compensation tied to the offerings, amended indemnification agreements for directors and officers, and an increase in authorized common shares to 800,000,000 via a certificate of amendment.
Helius Medical Technologies entered a new sales agreement with Clear Street and Maxim Group that allows it to sell Class A common stock from time to time in an at-the-market offering with an aggregate sales price of up to $92.8 million under its existing shelf registration.
The agents will receive up to 3% of gross proceeds as commission, and the company agreed to reimburse up to $75,000 of certain legal expenses. Separately, stockholders approved increasing authorized common shares to 800,000,000, and the company plans to amend its certificate of incorporation to reflect this higher authorization.
Helius Medical Technologies filed a prospectus supplement for an at-the-market equity program to sell up to $92.8 million of Class A common stock and disclosed a contemporaneous PIPE (cash and cryptocurrency) and advisory agreements dated September 15, 2025. The company reported a last Nasdaq sale price of $7.56 per share and expects the PIPE to close on or about September 18, 2025, subject to customary conditions and stockholder approvals for certain warrants.
Management intends to use net proceeds primarily to acquire SOL (Solana) tokens and to support a Solana-centric digital asset treasury, with Pantera engaged as strategic and trading advisor. The filing discloses recent corporate actions including reverse stock splits, increases in authorized shares, prior private placements and Nasdaq compliance remediation; Nasdaq confirmed regained compliance but the company will be monitored until July 7, 2026. The supplement emphasizes significant regulatory, custody, staking and market risks tied to the Solana strategy and potential dilution from multiple warrant and financing arrangements.
Helius Medical Technologies entered into private placement agreements to sell Cash Securities and Cryptocurrency Securities consisting of shares, pre-funded warrants and stapled warrants priced at $6.881 per share (pre-funded warrants priced at $6.880) with stapled warrants exercisable at $10.134. Cryptocurrency purchasers will pay with Unlocked or Locked SOL tokens; cash purchasers may use USD, USDC or USDT. Cryptocurrency warrants require stockholder approval before issuance for certain shares and the company will call a special meeting as soon as practicable. Pantera and Summer were engaged as strategic advisors and Pantera will also manage the company’s digital assets under a 10-year trading advisory with tiered AUM fees (1.0% to 0.5%). Advisor and PIPE lock-up periods apply and advisor warrants equal to 10% (7% Pantera, 3% Summer) of the Cash and pre-funded warrant shares were issued, with additional performance-based warrants tied to stapled warrant exercises. Summer is controlled by Joseph Chee, who is expected to be named Executive Chairman following closing.